<DOC>
	<DOC>NCT02139007</DOC>
	<brief_summary>This is a pilot study evaluating the recruitment strategies for sites and patients, data collection instruments, follow-up procedures, administrative processes, and the proposed management strategy for the future large scale national trial. This pilot study is 6 months in length.</brief_summary>
	<brief_title>Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>1.Females 65+ 2.3+ years of alendronate (Fosamax/Binosto) use 3. Valid social security number 1. History of any other metabolic bone condition, such as Paget Disease of Bone 2. Currently receiving treatment for ongoing cancer, excluding nonmelanoma skin cancer. 3. Has significant underlying illness that would be expected to prevent completion of the study (e.g., lifethreatening disease likely to limit survival to less than 3 years)? 4. HIV positive 5. Involved in a conflicting (investigational drug) clinical trial</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>